https://www.selleckchem.com/pr....oducts/lirafugratini
671; P .00001). Among 23 patients with documented listing status, 78.3% were listed for HT. Thirteen of 28 patients (46.4%) underwent HT at 14.4 ± 7.0 months. There were no reported deaths for the HT-free 1-year period. Median follow-up was 24 months (interquartile range, 12-30 months). Twenty-two of 28 patients (78.6%) achieved the composite outcome (BMI of35 kg/m /HT/listing for HT/myocardial recovery) at 11 months (interquartile range, 3-17 months). Patients with a BMI45 kg/m had a higher chance of achieving the co
Like
Comment
Share
